Patents by Inventor Avi J. Ashkenazi

Avi J. Ashkenazi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VASCULAR DISRUPTION AGENTS AND USES THEREOF
    Publication number: 20170290883
    Abstract: Uses of Apo2L/TRAIL polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided.
    Type: Application
    Filed: November 18, 2016
    Publication date: October 12, 2017
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • VASCULAR DISRUPTION AGENTS AND USES THEREOF
    Publication number: 20140178398
    Abstract: Uses of Apo2L/TRAIL polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided.
    Type: Application
    Filed: May 2, 2012
    Publication date: June 26, 2014
    Applicant: Genentech, Inc
    Inventor: Avi J. Ashkenazi
  • Method of inducing apoptosis using anti-DR5 antibodies
    Patent number: 8409570
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: April 2, 2013
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • ASSAYS AND METHODS USING BIOMARKERS
    Publication number: 20130072429
    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of GalNac-T related molecules, such as GalNac-T14 or GalNac-T3, is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Kits and articles of manufacture are also provided.
    Type: Application
    Filed: April 11, 2012
    Publication date: March 21, 2013
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Klaus W. Wagner
  • ASSAYS AND METHODS USING BIOMARKERS
    Publication number: 20120328603
    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.
    Type: Application
    Filed: November 23, 2011
    Publication date: December 27, 2012
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Klaus W. Wagner
  • METHODS AND COMPOSITIONS FOR MODULATING TWEAK AND FN14 ACTIVITY
    Publication number: 20120269808
    Abstract: Agonists and antagonists which modulate the activity of TWEAK and TWEAK receptor are provided. The methods, compositions and kits of the invention may be employed in the treatment of disorders such as cancer and immune-related diseases.
    Type: Application
    Filed: November 21, 2011
    Publication date: October 25, 2012
    Applicant: Genentech, Inc.
    Inventors: AVI J. ASHKENAZI, Heather Maecker
  • METHODS AND COMPOSITIONS RELATING TO ZPA POLYPEPTIDES
    Publication number: 20120266262
    Abstract: The present invention provides ZPA polypeptides, antibodies, nucleic acid molecules, antagonists, agonists, potentiators and compositions relating to ZPA polypeptides, and methods of identifying, making and using the same, that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides model systems for the intrinsic apoptotic pathway.
    Type: Application
    Filed: April 25, 2012
    Publication date: October 18, 2012
    Inventors: Avi J. Ashkenazi, Reece Hart, Erica Kratz, Kiran Mukhyala
  • Methods of using death receptor agonists and EGFR inhibitors
    Publication number: 20120189573
    Abstract: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with EGFR inhibitors, such as Tarceva™.
    Type: Application
    Filed: August 1, 2011
    Publication date: July 26, 2012
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • DR5 ANTIBODIES AND USES THEREOF
    Publication number: 20120087922
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Application
    Filed: September 7, 2011
    Publication date: April 12, 2012
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • Methods for making Apo-2 Ligand using divalent metal ions
    Publication number: 20120077740
    Abstract: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.
    Type: Application
    Filed: December 10, 2010
    Publication date: March 29, 2012
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Sarah Hymowitz, Robert F. Kelley, Iphigenia Koumenis, Woon-Lam Susan Leung, Mark O'Connell, Roger Pai, Zahra Shahrokh, Laura Simmons
  • Assays and methods using biomarkers
    Patent number: 8124339
    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: February 28, 2012
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Klaus W. Wagner
  • RTD RECEPTOR
    Publication number: 20120042400
    Abstract: Novel polypeptides, designated RTD, which are capable of binding Apo-2 ligand are provided. Compositions including RTD chimeras, nucleic acid encoding RTD, and antibodies to RTD are also provided.
    Type: Application
    Filed: November 29, 2010
    Publication date: February 16, 2012
    Applicant: GENENTECH, INC.
    Inventors: Avi J. Ashkenazi, Austin Gurney
  • TAT294 polypeptides
    Patent number: 8097700
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: January 17, 2012
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Dan L. Eaton, Audrey Goddard, Austin L. Gurney, William I. Wood, Thomas D. Wu
  • Antibodies to Apo-2 receptor polypeptides
    Patent number: 8092799
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: January 10, 2012
    Assignee: Genentech, Inc.
    Inventors: Camellia W Adams, Avi J Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 8084200
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: December 27, 2011
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Gretchen Frantz, Audrey Goddard, Lino Gonzalez, Austin L. Gurney, Paul Polakis, Andrew Polson, William I. Wood, Thomas D. Wu, Zemin Zhang
  • Nucleic acid encoding DR5 antibodies and uses thereof
    Patent number: 8030023
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • DR5 antibodies and articles of manufacture containing same
    Patent number: 8029783
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • Apo-2 Ligand
    Publication number: 20110183916
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Application
    Filed: September 22, 2010
    Publication date: July 28, 2011
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Ralph H. Schwall
  • Apo-2 ligand
    Publication number: 20110155605
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Application
    Filed: August 13, 2010
    Publication date: June 30, 2011
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • APO-2 receptor polypeptides
    Patent number: 7939631
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: May 10, 2011
    Assignee: Genentech, Inc.
    Inventor: Avi J. Ashkenazi